"This technology gives us a powerful tool to detect prostate cancer earlier and more precisely,” said Dr. James Howard.

An experimental immunotherapy drug called VIR-5500 has driven prostate-specific antigen (PSA) levels down by as much as 99% in some men with metastatic castration-resistant prostate cancer, according ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels.

FDA approved Pylarify TruVu, a higher-radioactivity-concentration formulation of piflufolastat F 18 designed to increase batch size and distribution efficiency while maintaining the established ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Editor's note: Dr. Jamin Brahmbhatt is a urologist and robotic surgeon with Orlando Health and an assistant professor at the University of Central Florida’s College of Medicine.When I learned that ...

This article was reviewed by Darragh O’Carroll, MD. PSA and Testosterone: Are They Linked? Prostate-specific antigen (PSA) is a term you’ll probably become familiar with once you start getting ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Early trials of the drug VIR-5500 showed it shrinking tumours in some patients ...

New prostate cancer drug showing ‘remarkable’ results during clinical trial - The new drug, known as VIR-5500, uses a ...